Maroussia Roelens

Dr. Maroussia Roelens

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Astronomy & Astrophysics
Verified
Journal Article
Open access
PDF file
LEL Eyer
L Eyer
MAM Audard
M Audard
BHB Holl
B Holl
LRL Rimoldini
L Rimoldini
MMMaria Isabel Carnerero Martin
Maria Isabel Carnerero Martin
MSM Süveges
M Süveges
Context.Gaiahas been in operations since 2014, and two full data releases (DR) have been delivered so far: DR1 in 2016 and DR2 in 2018. The thirdGaiadata release expands from the early data release (EDR3) in 2020, which contained the five-parameter astrometric solution and mean photometry for 1.8 billion sources by providing 34 months of multi-epoch observations that allowed us to systematically probe, characterise, and classify variable celestial phenomena.Aims.We present a summary of the variability processing and analysis of the photometric and spectroscopic time series of 1.8 billion sources carried out forGaiaDR3.Methods.We used statistical and machine learning methods to characterise and classify the variable sources. Training sets were built from a global revision of major published variable star catalogues. For a subset of classes, specific detailed studies were conducted to confirm their class membership and to derive parameters that are adapted to the peculiarity of the considered class.Results.In total, 10.5 million objects are identified as variable inGaiaDR3 and have associated time series inG,GBP, andGRPand, in some cases, radial velocity time series. The DR3 variable sources subdivide into 9.5 million variable stars and 1 million active galactic nuclei or ‘quasars’. In addition, supervised classification identified 2.5 million galaxies thanks to spurious variability induced by the extent of these objects. The variability analysis output in the DR3 archive amounts to 17 tables, containing a total of 365 parameters. We publish 35 types and subtypes of variable objects. For 11 variable types, additional specific object parameters are published. Here, we provide an overview of the estimated completeness and contamination of most variability classes.Conclusions.Thanks toGaia, we present the largest whole-sky variability analysis based on coherent photometric, astrometric, and spectroscopic data. FutureGaiadata releases will more than double the span of time series and the number of observations, allowing the publication of an even richer catalogue.

15 September 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MRMaroussia Roelens
Maroussia Roelens
GMGiovanni Battista Migliori
Giovanni Battista Migliori
LRLiudmila Rozanova
Liudmila Rozanova
JEJanne Estill
Janne Estill
JCJonathon R. Campbell
Jonathon R. Campbell
MRMario Raviglione
Mario Raviglione
Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63–2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20–0.69) with linezolid only, 0.40 (95% CI, 0.21–0.77) with bedaquiline only, and 0.21 (95% CI, 0.12–0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice.

13 October 2025 in Applied Microbiology
Verified
Journal Article
Open access
PDF file
IBIlia Belotserkovsky
Ilia Belotserkovsky
CVCecile Vernochet
Cecile Vernochet
MRMaroussia Roelens
Maroussia Roelens
BBBenoît Beitz
Benoît Beitz
BABouthaina Ben Abdallah
Bouthaina Ben Abdallah
CVChristophe Vedrine
Christophe Vedrine
Impairment of the intestinal epithelial barrier, accompanied by local and systemic inflammation, underlies numerous human pathologies, including inflammatory bowel diseases, celiac disease, sepsis, as well as severe acute malnutrition. Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG (LGG®) have been shown in preclinical studies to strengthen the gut epithelial barrier and attenuate inflammation. This study aimed to compare the ability of four commercial strains of B. infantis, LGG, and their combination to mitigate inflammation-mediated epithelial damage using an in vitro immunocompetent intestinal model. A microfluidic mid-throughput platform OrganoPlate® was used to co-culture intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells (PBMCs). Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide (LPS), and probiotic-conditioned media were applied to the apical side of Caco-2 cells to assess effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics significantly protected the epithelium by modulating tight junction protein expression and promoting transcription of homeostatic cytokines, resulting in a “leak-tight” phenotype. These findings indicate that metabolites produced by B. infantis and/or LGG can protect the intestinal epithelium in vitro, warranting further in vivo studies to evaluate the translational relevance of this effect.

18 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IRIuliana-Pompilia Radu
Iuliana-Pompilia Radu
CBChiara Becchetti
Chiara Becchetti
JSJonas Schropp
Jonas Schropp
PSPatrick Schmid
Patrick Schmid
PKPatrizia Künzler-Heule
Patrizia Künzler-Heule
SSSwiss Hepatitis C Cohort Study
Swiss Hepatitis C Cohort Study
Introduction: The use of direct-acting antivirals (DAAs) has drastically changed the management of HCV-infected patients by achieving a 95–98% sustained virologic response (SVR) and reducing morbidity and mortality in this population. However, despite their effectiveness, controversy exists concerning the occurrence of oncologic events following DAA therapy. Aims and Methods: A retrospective analysis was conducted on data from the Swiss Hepatitis C Cohort Study, a prospective cohort involving patients with positive HCV viremia upon inclusion, enrolled in various Swiss centers from September 2000 to November 2021. To examine potential differences in the risk of intrahepatic tumor (IHT) occurrence and death among patients treated with direct-acting antivirals (DAAs), untreated patients, and those receiving interferon (IFN)-based therapy, a semiparametric competing risk proportional hazards regression model was used. Results: Among 4082 patients (63.1% male, median age 45 years; genotype 1: 54.1%; cirrhosis: 16.1%), 1026 received exclusive treatment with IFN-based regimens, and 1180 were treated solely with DAAs. Over a median follow-up of 7.8 years (range: 3.8–11.9), 179 patients (4.4%) developed intrahepatic tumors (IHT), and 168 (4.1%) experienced extrahepatic tumors (EHT). The 5-year cumulative incidence of IHT was 1.55% (95% CI 0.96–2.48) for IFN-based therapy, 4.27% (95% CI 2.93–6.2) for DAA and 0.89% (95% CI 0.4–1.99) for untreated patients. There was no statistically significant difference in the risk of developing IHT (HR = 1.34; 95% CI = [0.70; 2.58]; p = 0.380) or death (HR = 0.66; 95% CI = [0.43; 1.03]; p = 0.066) between patients treated with DAAs and those treated with IFN. Conclusions: The DAAs reduced the risk of death and were not associated with an increased risk of extrahepatic tumors (EHT). In the adjusted model, accounting for cirrhosis and high liver stiffness, the DAA treatment was associated with a higher risk of IHT occurrence compared with untreated patients, emphasizing the relevance of implementing standardized hepatocellular carcinoma (HCC) screening post-DAA treatment.

25 July 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMaroussia Roelens
Maroussia Roelens
BBBarbara Bertisch
Barbara Bertisch
DMDarius Moradpour
Darius Moradpour
ACAndreas Cerny
Andreas Cerny
NSNasser Semmo
Nasser Semmo
CSConstantin Sluka
Constantin Sluka
Background: With direct-acting antiviral agents (DAAs), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection may change over time. However, the emergence of such trends may be delayed by the slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited. Methods: We evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office death registry. Results: We included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for liver-related mortality than those never treated or treated unsuccessfully. Conclusions: Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.

31 May 2022 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SBSara Botero-Mesa
Sara Botero-Mesa
FCFlávio Coelho
Flávio Coelho
KNKenechukwu Nwosu
Kenechukwu Nwosu
BWBertil Wicht
Bertil Wicht
AVAkarsh Venkatasubramanian
Akarsh Venkatasubramanian
OKOlivia Keiser
Olivia Keiser
Emerging infectious diseases are a growing threat in sub-Saharan African countries, but the human and technical capacity to quickly respond to outbreaks remains limited. Here, we describe the experience and lessons learned from a joint project with the WHO Regional Office for Africa (WHO AFRO) to support the sub-Saharan African COVID-19 response.In June 2020, WHO AFRO contracted a number of consultants to reinforce the COVID-19 response in member states by providing actionable epidemiological analysis. Given the urgency of the situation and the magnitude of work required, we recruited a worldwide network of field experts, academics and students in the areas of public health, data science and social science to support the effort. Most analyses were performed on a merged line list of COVID-19 cases using a reverse engineering model (line listing built using data extracted from national situation reports shared by countries with the Regional Office for Africa as per the IHR (2005) obligations). The data analysis platform The Renku Project (https://renkulab.io) provided secure data storage and permitted collaborative coding.Over a period of 6 months, 63 contributors from 32 nations (including 17 African countries) participated in the project. A total of 45 in-depth country-specific epidemiological reports and data quality reports were prepared for 28 countries. Spatial transmission and mortality risk indices were developed for 23 countries. Text and video-based training modules were developed to integrate and mentor new members. The team also began to develop EpiGraph Hub, a web application that automates the generation of reports similar to those we created, and includes more advanced data analyses features (e.g. mathematical models, geospatial analyses) to deliver real-time, actionable results to decision-makers.Within a short period, we implemented a global collaborative approach to health data management and analyses to advance national responses to health emergencies and outbreaks. The interdisciplinary team, the hands-on training and mentoring, and the participation of local researchers were key to the success of this initiative.